AcquisitionOther
Aditxt, Inc. acquired Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Aditxt, Inc. -> Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense · $80 million
Since its inception in 2015, Appili has developed a diverse portfolio, including the FDA-approved LIKMEZ™ (previously ATI-1501), ATI-1701 biodefense program supported by a USD $14 million non-dilutive award from the U.S DoD.
Open source record (SEC) ↗